FreshRSS

🔒
❌ Acerca de FreshRSS
Hay nuevos artículos disponibles. Pincha para refrescar la página.
AnteayerTus fuentes RSS

Trajectories of cigarette smoking and exposure to welding fumes and their impact on lung cancer risks: a latent class modelling approach

Por: Kendzia · B. · Taeger · D. · Pohabeln · H. · Ahrens · W. · Wichmann · H.-E. · Jöckel · K.-H. · Brüning · T. · Behrens · T.
Objectives

Traditional epidemiological approaches usually assume a constant relationship between cumulative exposure and disease, which implies that exposure duration and intensity contribute equally to the studied outcome. But individuals with the same cumulative exposure but different temporal exposure patterns may show different risks. Trajectory classification is a good way to assess exposure–risk associations and leads to a better understanding of lifetime variability in exposure levels. Therefore, this study aimed to estimate lung cancer risk according to the exposure trajectory classes on welding fumes and cigarette smoking.

Design

Two population-based German case–control studies.

Participants

3498 male lung cancer cases and 3539 male control subjects.

Methods

Separate latent class mixed models (LCMM) were determined to identify profiles of exposure trajectories of cigarette smoking and occupational exposure to welding fumes. To investigate the risk of lung cancer by class membership, ORs with 95% CI were estimated via multiple logistic regression analyses.

Results

LCMM each identified four latent classes of smoking and welding-fume exposure. Classes of smokers showed much higher risk of lung cancer compared with never smokers or subjects exposed to welding fumes. Smokers in one class characterised with the highest exposure over the past 10 years had the highest adjusted lung cancer risk (OR=39; 95% CI 29 to 53). For welding, the highest lung cancer risks were found for the class in which exposure to welding fumes in the past 10 years prior to the diagnosis of lung cancer was highest and the duration of welding was also quite high (OR=1.71; 95% CI 0.92 to 3.15).

Conclusions

In summary, LCMM opens a new perspective on dose–effect relationships and could be employed to complement established epidemiological methods.

Implementing the MIRROR‐TCM Randomised Control Trial During the COVID‐19 Pandemic: A Mixed‐Methods Evaluation

ABSTRACT

Aim

To evaluate the implementation of the Transitional Care Model (TCM), an evidence-based, advanced practice registered nurse-led multi-component intervention, as part of a randomised controlled trial during the first year of the COVID-19 pandemic.

Design

Parallel convergent mixed-methods approach.

Methods

Data for this study were collected between June 2020 and February 2021. Data from 78 patients who received the intervention and 68 recorded meetings with system leaders and clinical teams were analysed using descriptive statistics, directed content analysis, and joint display.

Results

Fidelity to delivery of elements of the TCM components was variable, with the Hospital-to-Home visit elements having the widest range (14.3%–100%) and Maintaining Relationships elements having the highest range (97.3%–98.6%). There were 27 identified challenges and 15 strategies for implementing the TCM with fidelity during the pandemic.

Conclusion

The COVID-19 pandemic impacted all aspects of the delivery of the TCM across all sites. This historical event highlighted the need for services and support for patients and caregivers transitioning from the hospital to home.

Implications for Nursing and Patient Care

Evidence-based solutions are needed to enhance healthcare delivery and patient outcomes. Findings will guide nurses in implementing proven transitional care interventions.

Impact

Findings will inform the implementation and scaling of transitional care and other evidence-based interventions across diverse healthcare settings.

Reporting Method

GRAMMS reporting guidelines.

Patient or Public Contribution

No patient or public contribution.

Trial Registration

ClinicalTrials.gov identifier: NCT04212962. https://www.clinicaltrials.gov/study/NCT04212962?titles=NCT04212962&rank=1

❌